AU2022269145B2 - Fc mutant with altered binding to fc receptor - Google Patents

Fc mutant with altered binding to fc receptor

Info

Publication number
AU2022269145B2
AU2022269145B2 AU2022269145A AU2022269145A AU2022269145B2 AU 2022269145 B2 AU2022269145 B2 AU 2022269145B2 AU 2022269145 A AU2022269145 A AU 2022269145A AU 2022269145 A AU2022269145 A AU 2022269145A AU 2022269145 B2 AU2022269145 B2 AU 2022269145B2
Authority
AU
Australia
Prior art keywords
time
sequence
response value
fcmut
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022269145A
Other languages
English (en)
Other versions
AU2022269145A1 (en
Inventor
Fenggen FU
Zhihai WU
Shuaixiang ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics (Suzhou) Co Ltd
Original Assignee
Innovent Biologics (Suzhou) Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics (Suzhou) Co Ltd filed Critical Innovent Biologics (Suzhou) Co Ltd
Publication of AU2022269145A1 publication Critical patent/AU2022269145A1/en
Application granted granted Critical
Publication of AU2022269145B2 publication Critical patent/AU2022269145B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022269145A 2021-05-07 2022-05-06 Fc mutant with altered binding to fc receptor Active AU2022269145B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110495363 2021-05-07
CN202110495363.7 2021-05-07
CN202210436873 2022-04-25
CN202210436873.1 2022-04-25
PCT/CN2022/091187 WO2022233320A1 (zh) 2021-05-07 2022-05-06 与Fc受体结合改变的Fc突变体

Publications (2)

Publication Number Publication Date
AU2022269145A1 AU2022269145A1 (en) 2023-12-21
AU2022269145B2 true AU2022269145B2 (en) 2026-05-28

Family

ID=83932014

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022269145A Active AU2022269145B2 (en) 2021-05-07 2022-05-06 Fc mutant with altered binding to fc receptor

Country Status (8)

Country Link
US (1) US20240228579A1 (cg-RX-API-DMAC7.html)
EP (1) EP4335868A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516320A (cg-RX-API-DMAC7.html)
CN (1) CN117295760A (cg-RX-API-DMAC7.html)
AU (1) AU2022269145B2 (cg-RX-API-DMAC7.html)
CA (1) CA3218187A1 (cg-RX-API-DMAC7.html)
TW (1) TWI839729B (cg-RX-API-DMAC7.html)
WO (1) WO2022233320A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024333211A1 (en) * 2023-08-30 2026-03-19 Astellas Pharma Inc. Fc REGION VARIANT

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101987870A (zh) * 2004-07-15 2011-03-23 赞科股份有限公司 优化的Fc变体
CN108713027A (zh) * 2015-12-17 2018-10-26 詹森生物科技公司 特异性结合hla-dr的抗体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
TW201245227A (en) * 2011-03-29 2012-11-16 Roche Glycart Ag Antibody Fc variants
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
ES2597228T3 (es) * 2012-06-27 2017-01-17 F. Hoffmann-La Roche Ag Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
EP3494139B1 (en) * 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
US12024560B2 (en) * 2017-03-28 2024-07-02 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
CN112912395B (zh) * 2018-08-20 2024-08-23 辉瑞公司 抗gdf15抗体、组合物和使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101987870A (zh) * 2004-07-15 2011-03-23 赞科股份有限公司 优化的Fc变体
CN108713027A (zh) * 2015-12-17 2018-10-26 詹森生物科技公司 特异性结合hla-dr的抗体及其用途

Also Published As

Publication number Publication date
WO2022233320A1 (zh) 2022-11-10
AU2022269145A1 (en) 2023-12-21
TWI839729B (zh) 2024-04-21
TW202246313A (zh) 2022-12-01
EP4335868A4 (en) 2025-08-13
CA3218187A1 (en) 2022-11-10
US20240228579A1 (en) 2024-07-11
EP4335868A1 (en) 2024-03-13
JP2024516320A (ja) 2024-04-12
CN117295760A (zh) 2023-12-26